125 related articles for article (PubMed ID: 7836762)
1. Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy.
Kuge S; Miura Y; Nakamura Y; Mitomi T; Habu S; Nishimura T
J Immunol; 1995 Feb; 154(4):1777-85. PubMed ID: 7836762
[TBL] [Abstract][Full Text] [Related]
2. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
4. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells.
Dobashi H; Seki S; Habu Y; Ohkawa T; Takeshita S; Hiraide H; Sekine I
Hepatology; 1999 Aug; 30(2):430-6. PubMed ID: 10421651
[TBL] [Abstract][Full Text] [Related]
5. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
[TBL] [Abstract][Full Text] [Related]
6. [An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].
Nishimura T; Kuge S; Watanabe K; Lee U; Yahata T; Habu S
Hum Cell; 1994 Sep; 7(3):131-7. PubMed ID: 7873496
[TBL] [Abstract][Full Text] [Related]
7. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen.
Kuroda K; Yagi J; Imanishi K; Yan XJ; Li XY; Fujimaki W; Kato H; Miyoshi-Akiyama T; Kumazawa Y; Abe H; Uchiyama T
J Immunol; 1996 Aug; 157(4):1422-31. PubMed ID: 8759722
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
9. Superantigens anergize cytokine production but not cytotoxicity in vivo.
Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T
Immunology; 1994 May; 82(1):117-25. PubMed ID: 7913912
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-18 regulates T helper 1 or 2 immune responses of human cord blood CD4+ V alpha 24+V beta 11+ natural killer T cells.
Fujibayashi Y; Fujimori Y; Kasumoto I; Kai S; Hara H; Okamura H; Tsutsui H; Ogawa H; Nakanishi K
Int J Mol Med; 2007 Aug; 20(2):241-5. PubMed ID: 17611643
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
12. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
13. Staphylococcal enterotoxin B activates purified NK cells to secrete IFN-gamma but requires T lymphocytes to augment NK cytotoxicity.
D'Orazio JA; Burke GW; Stein-Streilein J
J Immunol; 1995 Feb; 154(3):1014-23. PubMed ID: 7529788
[TBL] [Abstract][Full Text] [Related]
14. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
15. Th1 development of naive CD4+ T cells is inhibited by co-activation with anti-CD4 monoclonal antibodies.
Goedert S; Germann T; Hoehn P; Koelsch S; Palm N; Rüde E; Schmitt E
J Immunol; 1996 Jul; 157(2):566-73. PubMed ID: 8752903
[TBL] [Abstract][Full Text] [Related]
16. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
17. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
[TBL] [Abstract][Full Text] [Related]
18. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
19. Signal requirement for induction of MHC-unrestricted antitumor cytotoxicity of human T cell CD4+/CD8+ subpopulations.
Zhu HG; Klein-Franke A; Anderer FA
Anticancer Res; 1994; 14(3A):953-61. PubMed ID: 8074498
[TBL] [Abstract][Full Text] [Related]
20. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes.
Garcia-Mauriño S; Gonzalez-Haba MG; Calvo JR; Rafii-El-Idrissi M; Sanchez-Margalet V; Goberna R; Guerrero JM
J Immunol; 1997 Jul; 159(2):574-81. PubMed ID: 9218571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
